跳至主要内容
临床试验/NCT02291354
NCT02291354Unknown2 期

A Randomized, Controlled Study of Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Adult Patients With Slow Transit Constipation

Jinling Hospital, China1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
50
试验地点
1
主要终点
Proportion of patients having on average three or more SCBMs/week

研究概览

简要总结

The purpose of this study is to evaluate the synergism of Soluble Dietary Fiber with Fecal Microbiota Transplantation in Adult Patients with Slow Transit Constipation.

详细描述

Constipation is a chronic disease estimated to affect about 10% - 15% of the worldwide general population. Recent evidence in the literature and collected in our laboratory confirm that constipation can be a consequence of intestinal dysbiosis, which may affect the motility and metabolic environment of colon.

Fecal Microbiota Transplantation (FMT) is temporarily effective for patients with slow transit constipation. However, the transplanted microflora cannot maintain for a long time. Along with the gut microbiota returning to the original state, the symptoms relapse.

Pectin is a kind of soluble dietary fiber, producing short chain fatty acids (SCFAs) after a series of fermentation by gut flora to supply the energy for epithelial cells, regulate intestinal PH, promote intestinal motility and join effort in immune regulation with intestinal lymphoid tissue. Therefore, we conceive that pectin could promote the colonization of probiotics and reduce adhesion of pathogens.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Chronic constipation according to Rome III criteria, defined as two or fewer spontaneous, complete bowel movements (SCBMs) per week for a minimum of 6 months;
  • Age ≥ 18 years;
  • BMI: 18.5-25 kg/m2;
  • Slow colonic transit confirmed by colonic transit test (colonic transit time (CTT) > 48 hours);
  • Normal anorectal manometry, with no evidence of dyssynergia and confirmed ability to expel rectal balloon;
  • No radiographic evidence of functional (i.e. pelvic floor dyssynergia) or anatomical (i.e. significant rectocele and intussusception) impediment to the expulsion of the radio-opaque contrast;
  • Disease duration > 1 year;
  • Traditional treatment with dietary modification, laxatives (including osmotic and stimulant laxatives), and biofeedback tried over the past 6 months without success;

排除标准

  • Bowel constipation due to innate factor (i.e. megacolon) or secondary interventions (i.e. drugs, endocrine, metabolic, neurologic or psychologic disorders);
  • History or evidence of gastrointestinal diseases (i.e. obstruction, cancer, inflammatory bowel diseases) ;
  • Previous abdominal surgery, except cholecystectomy, appendicectomy, tubal ligation and cesarean section;
  • Previous proctological or perianal surgery;
  • A constipation condition meeting the Rome III criteria for IBS or functional abdominal pain syndrome;
  • Pregnant or breast-feeding women;
  • Infection with enteric pathogen;
  • Usage of probiotics, prebiotics and/or synbiotics within the last month;
  • Usage of antibiotics and/or PPIs within the last 3 months;
  • Smoking or alcohol addiction within the last 3 months;
  • Uncontrolled hepatic, renal, cardiovascular, respiratory or psychiatric disease;
  • Disease or therapy with drugs (i.e. antidepressants, opioid narcotic analgesics, anticholinergics, calcium antagonists, nitrates, antimuscarinics) that, in the opinion of the investigator, could affect intestinal transit and microbiota.

研究组 & 干预措施

FMT + Placebo

Placebo Comparator

Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.

干预措施: Placebo (Other)

FMT + Placebo

Placebo Comparator

Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.

干预措施: Fecal microbiota transplantation (FMT) (Procedure)

FMT + Pectin

Experimental

Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.

干预措施: Pectin (Drug)

FMT + Pectin

Experimental

Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.

干预措施: Fecal microbiota transplantation (FMT) (Procedure)

结局指标

主要结局

Proportion of patients having on average three or more SCBMs/week

时间窗: 12 weeks

Proportion of patients having on average three or more spontaneous, complete bowel movements (SCBMs) per week was evaluated at week 4 and 12.

次要结局

  • Colonic transit time measurements(12 weeks)
  • Usage of laxatives or enemas as rescue medication(12 weeks)
  • Bowel habit assessments(12 weeks)
  • Constipation-related symptoms assessments(12 weeks)
  • Quality-of-Life assessments(12 weeks)
  • Adverse events(12 weeks)

研究者

发起方
Jinling Hospital, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jianfeng Gong

Associate professor

Jinling Hospital, China

研究点 (1)

Loading locations...

相似试验